Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Zimpfer, D; Fiane, AE; Larbalestier, R; Tsui, S; Jansz, P; Simon, A; Schueler, S; Strueber, M; Schmitto, JD.
Long-Term Survival of Patients With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended as a Bridge to Transplantation: The Registry to Evaluate the HeartWare Left Ventricular Assist System.
Circ Heart Fail. 2020; 13(3):e006252
Doi: 10.1161/CIRCHEARTFAILURE.119.006252
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Zimpfer Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The paucity of available hearts for transplantation means that more patients remain on durable left ventricular support for longer periods of time. The Registry to Evaluate the HeartWare Left Ventricular Assist System was an investigator-initiated multicenter, prospective, single-arm database established to collect post-Conformité Européene mark clinical information on patients receiving the HeartWare ventricular assist device system as a bridge to transplantation. This registry represents the longest multicenter follow-up of primary left ventricular assist device outcomes. METHODS: Data were collected on 254 commercial implants performed between February 2009 and March 2012 from 9 centers in Europe (7) and Australia (2). Patients were followed to device explant, heart transplantation, or death. The outcomes of patients through July/August 2018 were analyzed. Summary statistics were used to describe patient demographics, adverse events, length of support, and outcomes for this extended-term cohort. RESULTS: A total of 122 patients were on support for >2 years, and 34 patients were on support for >5 years. Twenty nine patients are still alive on support (support ranging from 1213 to 3396 days), and 23 of those are on their original HeartWare ventricular assist device system. Kaplan-Meier survival through 7 years was 51%. Through 6 years, freedom from any stroke was 82%, while freedom from severely disabling stroke was 89%. CONCLUSIONS: Low rates of heart transplant now require longer periods of left ventricular assist device support in patients. This analysis demonstrates that long-term support using a HeartWare ventricular assist device system offers survival of 51% through 7 years.
- Find related publications in this database (using NLM MeSH Indexing)
- Australia - administration & dosage
- Europe - administration & dosage
- Female - administration & dosage
- Heart Failure - diagnosis, mortality, physiopathology, therapy
- Heart Transplantation - administration & dosage
- Heart-Assist Devices - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prosthesis Design - administration & dosage
- Prosthesis Implantation - adverse effects, instrumentation, mortality
- Recovery of Function - administration & dosage
- Registries - administration & dosage
- Retrospective Studies - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Ventricular Function, Left - administration & dosage
- Waiting Lists - administration & dosage
- Find related publications in this database (Keywords)
- demography
- heart failure
- heart transplantation
- registries
- stroke